Revolution Medicines, Inc. (RVMD) Misses Q3 EPS by 5c

Revolution Medicines, Inc. (NASDAQ: RVMD) reported Q3 EPS of ($0.94), $0.05 worse than the analyst estimate of ($0.89). Revenue for the quarter came in at $0 versus the consensus estimate of $807.69 thousand.

For earnings history and earnings-related data on Revolution Medicines, Inc. (RVMD) click here.

You May Also Be Interested In

• Evercore ISI Starts Credo Tech (CRDO) at Outperform
• Increasing unusual put option volume: VTRS ACI STRC PURR BSOL HTZ CDNS
• WeRide partners with Geely Farizon and Kwoon Chung on right-hand-drive robotaxi